Multimodal Biopsychosocial Teleprehabilitation for Total Knee Arthroplasty
Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · Aug 19, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new program called multimodal biopsychosocial teleprehabilitation (BPS-teleprehab) for people who are scheduled to have total knee replacement surgery, also known as total knee arthroplasty (TKA). The goal of this program is to prepare patients better for their surgery by providing information and support before the procedure, helping them to recover more effectively afterward, and improving their overall experience. Researchers want to find out if this program is safe, acceptable, and helpful compared to the usual preoperative advice given to patients.
To be eligible for this trial, participants should be adults over 18 years old who are scheduled for elective knee replacement surgery and can read and understand Dutch. However, individuals who are very active (doing strenuous activities for more than 300 minutes a week), have certain health conditions that could affect their ability to exercise safely, or have cognitive impairments are not eligible. If you join the study, you can expect to receive guidance and support through telehealth (online sessions), which will help you prepare for surgery and rehabilitation. This trial aims to gather important information that could lead to a larger study in the future, potentially improving care for many patients undergoing knee replacement surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • People scheduled for elective primary TKA at one of the participating hospitals;
- • Being over 18 years old;
- • Dutch speaking/reading
- Exclusion Criteria:
- • Doing activities that make them feel out of breath for 300 minutes or more per week on average;
- • Orthopedic, neurological, cardiovascular or any other condition/comorbidity that leads to an overall contraindication for moderate physical activity;
- • Cognitive impairment (≥11 on 6-item Cognitive Impairment Test and/or unable to understand the study instructions);
- • Presence of uncontrolled inflammatory arthritides (e.g., rheumatoid arthritis, gout);
- • Uncontrolled psychiatric disorders;
- • Active cancer and/or active cancer treatment ((hormonal) maintenance therapy is allowed);
- • People undergoing emergency (non-elective) TKA.
About Universitair Ziekenhuis Brussel
Universitair Ziekenhuis Brussel (UZ Brussel) is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution affiliated with the Vrije Universiteit Brussel, UZ Brussel integrates cutting-edge medical research with high-quality patient care. The hospital's multidisciplinary teams are dedicated to exploring novel therapeutic approaches and contributing to the development of evidence-based treatments, ensuring the highest standards of safety and efficacy in clinical research. With a strong focus on collaboration and knowledge dissemination, UZ Brussel plays a pivotal role in shaping the future of medicine and improving patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Geel, Antwerpen, Belgium
Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Patients applied
Trial Officials
Eva Huysmans, PhD
Principal Investigator
Vrije Universiteit Brussel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported